Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open-label Study of ARX788 (Anti-HER2 Antibody Drug Conjugate (ADC)) for Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

NCT06224673 is registered in ClinicalTrials.gov with Laura Huppert, MD, BA as lead sponsor.

NCT NCT06224673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06224673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open-label Study of ARX788 (Anti-HER2 Antibody Drug Conjugate (ADC)) for Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
Lead sponsor
Laura Huppert, MD, BA
Phase
Phase 2
Overall status
Recruiting
Start date
June 5, 2026
Completion date
November 30, 2029
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2 low breast carcinoma, hormone receptor positive breast carcinoma, hormone-receptor-positive breast cancer, triple negative breast cancer